Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Positive NCX 470 Phase 3 Data highlighted at the 2026 AGS
February 24, 2026
What is the news ?
Nicox highlighted positive Phase 3 data for NCX 470 at the 2026 American Glaucoma Society Annual Meeting, demonstrating strong intraocular pressure reduction and a favorable safety profile.
What does it mean ?
The results reinforce the therapeutic potential of NCX 470 and support its regulatory positioning as a potential new treatment option for patients with glaucoma or ocular hypertension.